Product-Related Impurity Analysis per ICH Q6B: Chromatography & Mass Spectrometry
What Are Product-Related Impurities?
Product-related impurities are molecular variants of the active drug substance that arise from degradation, modification, or alternative folding during manufacturing, purification, or storage. They differ from the target drug molecule in structure, potency, efficacy, or safety profile — and must be identified, characterized, and controlled to ensure that the final drug product is both safe and efficacious.
ICH Q6B (Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products) defines product-related impurities as “molecular variants of the desired product formed during manufacture and/or storage” — requiring that each significant impurity be identified, characterized, and controlled within qualified limits. This is a critical regulatory and quality requirement across the biopharmaceutical, biosimilar, and advanced therapy industries.
Types of Product-Related Impurities in Biopharmaceuticals
Protein Variants (Biotechnology-Derived Products)
- Deamidated forms: Asparagine and glutamine residues undergo deamidation to aspartate and glutamate — altering charge heterogeneity, protein conformation, and potentially bioactivity
- Oxidized forms: Methionine, cysteine, and tryptophan are susceptible to oxidative degradation — changing folding and receptor binding properties
- Mismatched disulfide-linked variants: Incorrect S-S bond formation between non-native cysteine pairs — reducing potency
- Glycosylation variants: Altered N-linked or O-linked glycan structures — affecting half-life, immunogenicity, and Fc receptor binding (for antibodies)
- Aggregated species: Soluble and insoluble protein aggregates — immunogenicity concern and potential loss of potency
- Clipped/truncated fragments: N-terminal or C-terminal truncations from proteolytic cleavage — different receptor binding affinity
Small Molecule Drug Variants
- Degradation products: Hydrolysis, photodegradation, or oxidation products exceeding ICH Q3B thresholds
- Epimers and stereoisomers: Non-specified stereochemical configurations with potentially different pharmacology
Laboratory-Scale Isolation for Characterization
A key requirement of ICH Q6B characterization is isolating sufficient quantities of each significant impurity for structural elucidation and safety assessment. Laboratory-scale isolation techniques used for this purpose include:
- Preparative HPLC / Reversed-Phase Chromatography: Isolates individual impurity peaks from complex product mixtures to milligram quantities for NMR and mass spectrometry confirmation
- Ion Exchange Chromatography (IEX): Separates charge variants (deamidated, sialylated, and glycoform species) from the main product isoform for individual characterization
- Size Exclusion Chromatography (SEC): Isolates high-molecular-weight aggregates and low-molecular-weight fragments from monomeric drug substance
- Hydrophobic Interaction Chromatography (HIC): Separates oxidized variants based on altered hydrophobicity after oxidative modification
Analytical Characterization Methods
Chromatographic Methods
| Method | Impurity Type Characterized |
| Reversed-phase HPLC (RP-HPLC) | Oxidized and deamidated variants; peptide mapping |
| Cation exchange (CEX-HPLC) | Charge variants; deamidated, sialylated forms |
| Anion exchange (AEX-HPLC) | Glycoform separation |
| Size exclusion (SEC-HPLC) | Aggregates, dimers, fragments |
| Hydrophobic interaction (HIC-HPLC) | Oxidized variants; conformational changes |
Mass Spectrometry Methods
- LC-MS/MS (tandem mass spectrometry): Peptide mapping with MS/MS fragmentation identifies site-specific modifications (deamidation, oxidation, glycosylation sites) at single amino acid resolution
- MALDI-TOF MS: Intact protein molecular weight and glycoform distribution
- Native MS / Ion Mobility MS: Non-denaturing analysis of protein complex stoichiometry and aggregate species characterization
Other Characterization Methods
- NMR spectroscopy: Structural confirmation of isolated impurities — particularly for small molecules and glycan structures
- Capillary Electrophoresis (CE, cIEF): Charge heterogeneity profiling; glycan analysis by CE-LIF
- Fluorescence spectroscopy: Tryptophan oxidation monitoring; aggregate detection by intrinsic fluorescence
Conclusion
Product-related impurity analysis per ICH Q6B is a comprehensive, multi-technique analytical program — requiring isolation of individual impurities, structural characterization to confirm identity, and quantitative methods for ongoing lot release monitoring. The scientific rigor of this analysis directly supports the regulatory approval and ongoing commercial manufacturing of safe, consistent biotechnology products.
Partnering with Infinita Lab for Biopharmaceutical Impurity Analysis
Infinita Lab addresses the most frustrating pain points in the product-related impurity testing process: complexity, coordination, and confidentiality. Our GLP/GMP-compliant laboratories offer an extensive array of isolation techniques and characterization technologies — ensuring that drug substances conform to all regulatory expectations. From kickoff to final report, we orchestrate every detail, fast and seamlessly.
Looking for a trusted partner to achieve your research goals? Schedule a meeting with us, send us a request, or call us at (888) 878-3090 to learn more about our services and how we can support you. Request a Quote
Frequently Asked Questions (FAQs)
What is the ICH Q6B threshold for reporting and characterizing product-related impurities? ICH Q6B does not specify fixed numerical thresholds for biotechnology products as ICH Q3A/B does for small molecules. Instead, it requires characterization of all impurities that might affect safety, efficacy, or stability — typically those >0.1% of the main peak by area, and any impurity with a unique safety concern regardless of level.
How is deamidation detected and quantified in biopharmaceutical products? Deamidation is detected by peptide mapping with LC-MS/MS — comparing intact and modified peptide masses after tryptic digestion. The mass shift of +0.984 Da distinguishes aspartate (deamidated) from asparagine (original). Charge-based methods (CEX-HPLC, cIEF) quantify total charge variant distribution including deamidated species.
Why are protein aggregates considered a critical product-related impurity? Protein aggregates are a primary safety concern in biopharmaceuticals — they are associated with immunogenicity risk because repeated particle exposure can prime immune responses against the therapeutic protein. ICH Q6B requires characterization of aggregate species; regulatory agencies require aggregate levels to be controlled and monitored throughout the product's commercial lifecycle.
What is the role of peptide mapping in product-related impurity characterization? Peptide mapping by RP-HPLC-MS/MS provides a site-specific survey of all modifications on every peptide in the protein — identifying deamidation, oxidation, glycosylation, cleavage sites, and disulfide bond mismatches at the single amino acid level. It is the most comprehensive single analytical tool for biotechnology product characterization.
When is laboratory-scale isolation of impurities required by ICH Q6B? Isolation is required when an impurity at a significant level cannot be definitively characterized by in-situ analytical methods alone — typically when structural elucidation requires NMR, or when sufficient material must be produced for toxicological assessment, reference standard preparation, or in vitro potency comparison. Milligram quantities are typically required for comprehensive characterization programs.
